Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) Shares Outstanding (2020 - 2025)

Historic Shares Outstanding for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to $172.6 million.

  • Relay Therapeutics' Shares Outstanding rose 344.22% to $172.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $172.6 million, marking a year-over-year increase of 344.22%. This contributed to the annual value of $167.8 million for FY2024, which is 3161.19% up from last year.
  • Relay Therapeutics' Shares Outstanding amounted to $172.6 million in Q3 2025, which was up 344.22% from $171.7 million recorded in Q2 2025.
  • Relay Therapeutics' Shares Outstanding's 5-year high stood at $172.6 million during Q3 2025, with a 5-year trough of $90.4 million in Q1 2021.
  • Its 5-year average for Shares Outstanding is $129.1 million, with a median of $121.9 million in 2023.
  • Per our database at Business Quant, Relay Therapeutics' Shares Outstanding tumbled by 5747.4% in 2021 and then skyrocketed by 3550.28% in 2024.
  • Relay Therapeutics' Shares Outstanding (Quarter) stood at $108.2 million in 2021, then increased by 11.92% to $121.1 million in 2022, then grew by 5.24% to $127.5 million in 2023, then skyrocketed by 31.61% to $167.8 million in 2024, then grew by 2.91% to $172.6 million in 2025.
  • Its Shares Outstanding stands at $172.6 million for Q3 2025, versus $171.7 million for Q2 2025 and $170.5 million for Q1 2025.